2018
Rare case of radiation-induced primary tracheal carcinoma
Mori M, Detterbeck FC. Rare case of radiation-induced primary tracheal carcinoma. General Thoracic And Cardiovascular Surgery 2018, 66: 549-551. PMID: 29546552, DOI: 10.1007/s11748-018-0907-0.Peer-Reviewed Original Research
2016
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, van Schil P, Yatabe Y, Members I, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer D, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Eberhardt W, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim Y, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom E, van Meerbeeck J, Mitchell A, Nakano T, Nicholson A, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier J, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas C, Travis W, Tsao M, Turrisi A, Vansteenkiste J, Watanabe H, Wu Y, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso P, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal Of Thoracic Oncology 2016, 11: 1204-1223. PMID: 27107787, DOI: 10.1016/j.jtho.2016.03.025.Peer-Reviewed Original ResearchConceptsPart-solid tumorsLepidic predominant adenocarcinomaTumor sizeLung cancerInternational Cancer Control tumorEighth editionWorld Health Organization classificationIASLC Lung Cancer Staging ProjectLung Cancer Staging ProjectForthcoming Eighth EditionNonmucinous lung adenocarcinomasPrimary tumor categoryComputed tomography findingsInvasive mucinous adenocarcinomaSquamous cell carcinomaGround-glass componentInvasive sizeTomography findingsClinical stagingMucinous adenocarcinomaPathologic evaluationResected specimensTNM classificationCell carcinomaMetastasis classificationDetection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)
Martin LW, D'Cunha J, Wang X, Herzan D, Gu L, Abraham N, Demmy TL, Detterbeck FC, Groth SS, Harpole DH, Krasna MJ, Kernstine K, Kohman LJ, Patterson GA, Sugarbaker DJ, Vollmer RT, Maddaus MA, Kratzke RA. Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). Journal Of Clinical Oncology 2016, 34: 1484-1491. PMID: 26926677, PMCID: PMC4872306, DOI: 10.1200/jco.2015.63.4543.Peer-Reviewed Original ResearchConceptsN2 lymph nodesStage I NSCLCDisease-free survivalOccult micrometastasesLymph nodesCell lung cancerOverall survivalLung cancerStage IClinical stage I NSCLCPathologic stage I NSCLCComplete surgical stagingClinical stage IRT-PCRDecreased overall survivalNegative lymph nodesWorse survival rateSquamous cell carcinomaReal-time reverse transcriptase-polymerase chain reactionMulti-institutional trialReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionWarrants further investigationSurgical stagingPrognostic significance
2015
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, Mukai K, Orazi A, Ströbel P. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. Journal Of Thoracic Oncology 2015, 10: 1383-1395. PMID: 26295375, PMCID: PMC4581965, DOI: 10.1097/jto.0000000000000654.Peer-Reviewed Original ResearchConceptsWorld Health Organization classificationThymic epithelial tumorsOrganization classificationEpithelial tumorsThymic squamous cell carcinomaPositron emission tomography/Squamous cell carcinomaGerm cell tumorsNew tumor entityEmission tomography/Soft tissue tumorsClassification of tumorsDendritic cellsMediastinal lymphomaThymic tumorsCell carcinomaCell tumorsThoracic surgeryTomography/Therapeutic decisionsThymus sectionsMyeloid neoplasmsTumor entitiesDiagnostic criteriaClinical relevance
2014
Thymic carcinoma outcomes and prognosis: Results of an international analysis
Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A. Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 95-101.e2. PMID: 25524678, DOI: 10.1016/j.jtcvs.2014.09.124.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'Proportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSex FactorsThymectomyThymomaThyroid NeoplasmsTime FactorsTreatment OutcomeConceptsRecurrence-free survivalEarly Masaoka stageR0 resectionOverall survivalRadiation therapyMasaoka stageThymic carcinomaMale genderLonger recurrence-free survivalMedian overall survivalStage IV diseaseAdjuvant radiation therapyMasaoka stage IPreoperative radiation therapyPrimary outcome measureSquamous cell carcinomaPredominant histologic subtypeAdjuvant chemotherapyImproved OSInduction chemotherapyProlonged OSCumulative incidenceHistologic subtypeMultivariable analysisTreatment patterns
2011
Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay
Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL. Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay. Cancer 2011, 118: 1607-1618. PMID: 22009766, DOI: 10.1002/cncr.26450.Peer-Reviewed Original Research
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2008
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer
Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 145-151. PMID: 18303435, DOI: 10.1097/jto.0b013e318160c5f1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDocetaxelDrug-Related Side Effects and Adverse ReactionsFeasibility StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPatient ComplianceSurvival AnalysisTaxoidsConceptsNon-small cell lung cancerCell lung cancerAdjuvant therapySupportive therapyChemotherapy complianceLung cancerAdequate exposureResected non-small cell lung cancerAdjuvant cisplatin-based chemotherapyMulticenter phase II trialMedian age 65 yearsCycles of therapyPrimary end pointAcceptable toxicity profileBetter functional statusPhase II trialCisplatin-based chemotherapyMajority of patientsSquamous cell carcinomaAge 65 yearsAdjuvant carboplatinCommon histologyII trialIntercurrent illnessActive therapy